Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARVINAS, INC.ARVN · Entity 5355 | Director | June 15, 2023 | June 20, 2023 |
| Alkermes plc.ALKS · Entity 2392 | Director | June 14, 2022 | June 16, 2022 |
| BRISTOL MYERS SQUIBB CO(BMY) · Entity 1662 | CMO & Pres, Global Marketing | May 22, 2006 | May 24, 2006 |
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | Director | March 15, 2024 | April 04, 2024 |
| Carisma Therapeutics Inc.SESN · Entity 74418 | Director | June 19, 2019 | June 21, 2019 |
| INCYTE CORPINCY · Entity 3182 | Director | March 31, 2022 | April 04, 2022 |
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Director | June 10, 2022 | June 14, 2022 |
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Director | June 04, 2020 | June 05, 2020 |
| ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212 | Director | May 29, 2025 | May 31, 2025 |
| bluebird bio, Inc.BLUE · Entity 78923 | Director | November 11, 2021 | November 17, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARVINAS, INC.
Report date June 15, 2023 · Filed June 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,121 |
Reported balance
After 2023-06-15 transaction · row 1
1 source rowRow 1 · 2023-06-15 · Grant · Acquired 4,121 · Balance 9,121 F1: The restricted stock units (each, an "RSU") were granted by the Issuer on June 15, 2023 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of June 15, 2024 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.33 · Expires 2033-06-14 | Direct | 12,787 |
Reported balance
After 2023-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-15 · Grant · Acquired 12,787 · Balance 12,787 F2: This option award was granted on June 15, 2023. The shares underlying the award shall vest in full on the earlier of June 15, 2024 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units (each, an "RSU") were granted by the Issuer on June 15, 2023 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of June 15, 2024 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders.
F2: This option award was granted on June 15, 2023. The shares underlying the award shall vest in full on the earlier of June 15, 2024 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders.
Alkermes plc.
Report date June 14, 2022 · Filed June 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 53,124 |
Reported balance
After 2022-06-14 transaction · row 1
1 source rowRow 1 · 2022-06-14 · Exercise / conversion · Acquired 7,585 · Balance 53,124 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-14 · Exercise / conversion · Disposed 7,585 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F2: This award is fully vested in accordance with its terms. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one ordinary share.
F2: This award is fully vested in accordance with its terms.
BRISTOL MYERS SQUIBB CO
Report date May 22, 2006 · Filed May 24, 2006
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 87,003 |
Reported balance
After 2006-05-22 transaction · row 1
1 source rowRow 1 · 2006-05-22 · Tax withholding · Disposed 3,396 · Balance 87,003 F1: Shares withheld for payment of taxes upon vesting of restricted stock. |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectBy BMY Savings & Investment Program | 1,543.43 |
Reported balance
Holding disclosure · report date 2006-05-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,543.43 F2: Based on a plan statement as of the end of the most recent fiscal quarter. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld for payment of taxes upon vesting of restricted stock.
F2: Based on a plan statement as of the end of the most recent fiscal quarter.
Black Diamond Therapeutics, Inc.
Report date March 15, 2024 · Filed April 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,054 |
Reported balance
After 2024-03-15 transaction · row 1
1 source rowRow 1 · 2024-03-15 · Grant · Acquired 3,253 · Balance 38,054 F1: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 14, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 14, 2024.
Carisma Therapeutics Inc.
Report date June 19, 2019 · Filed June 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2029-06-18 | Direct | 105,000 |
Reported balance
After 2019-06-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-19 · Grant · Acquired 105,000 · Balance 105,000 F1: The option was granted on June 19, 2019 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 19, 2019 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested.
INCYTE CORP
Report date March 31, 2022 · Filed April 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,768 |
Reported balance
After 2022-03-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-03-31 · Grant · Acquired 249 · Balance 17,768 F1: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.
F2: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
IOVANCE BIOTHERAPEUTICS, INC.
Report date June 10, 2022 · Filed June 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 51,204 |
Reported balance
After 2022-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-10 · Grant · Acquired 51,204 · Balance 51,204 F1: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).
F2: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.
Voyager Therapeutics, Inc.
Report date June 04, 2020 · Filed June 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.79 · Expires 2030-06-04 | Direct | 15,000 |
Reported balance
After 2020-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-04 · Grant · Acquired 15,000 · Balance 15,000 F1: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.
ZEVRA THERAPEUTICS, INC.
Report date May 29, 2025 · Filed May 31, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.62 · Expires 2035-05-28 | Direct | 30,000 |
Reported balance
After 2025-05-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-29 · Grant · Acquired 30,000 · Balance 30,000 F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 29, 2025. F2: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy. F3: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 29, 2025.
F2: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.
F3: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.
bluebird bio, Inc.
Report date November 11, 2021 · Filed November 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,894 |
Reported balance
After 2021-11-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-11-11 · Other · Acquired 6,241 · Balance 11,894 F1: Represents restricted stock units awarded to the reporting person prior to the separation (the "Separation") of 2seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"). In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the Employee Matters Agreement by and between 2seventy and bluebird (the "EMA") to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on June 15, 2021 and vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders. F2: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.07 · Expires 2023-04-29 | Direct | 25,953 |
Reported balance
After 2021-11-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-11 · Other · Disposed 26,361 · Balance 25,953 F4: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on April 29, 2013 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.54 · Expires 2024-06-11 | Direct | 7,384 |
Reported balance
After 2021-11-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-11 · Other · Disposed 7,500 · Balance 7,384 F5: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 11, 2014 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $92.14 · Expires 2025-06-04 | Direct | 7,384 |
Reported balance
After 2021-11-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-11 · Other · Disposed 7,500 · Balance 7,384 F6: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 4, 2015 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.85 · Expires 2026-06-02 | Direct | 3,938 |
Reported balance
After 2021-11-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-11 · Other · Disposed 4,000 · Balance 3,938 F7: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 2, 2016 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.29 · Expires 2027-06-08 | Direct | 3,938 |
Reported balance
After 2021-11-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-11 · Other · Disposed 4,000 · Balance 3,938 F8: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 8, 2017 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $91.20 · Expires 2028-06-20 | Direct | 3,938 |
Reported balance
After 2021-11-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-11-11 · Other · Disposed 4,000 · Balance 3,938 F9: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 20, 2018 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.78 · Expires 2029-06-06 | Direct | 3,938 |
Reported balance
After 2021-11-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-11-11 · Other · Disposed 4,000 · Balance 3,938 F10: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 6, 2019 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.93 · Expires 2030-06-18 | Direct | 2,953 |
Reported balance
After 2021-11-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-11-11 · Other · Disposed 3,000 · Balance 2,953 F11: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 18, 2020 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.36 · Expires 2031-06-15 | Direct | 10,038 |
Reported balance
After 2021-11-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-11-11 · Other · Disposed 5,000 · Balance 10,038 F12: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 15, 2021 and shall vest 100% on the earlier of June 15, 2022 or the date of the next annual meeting of the stockholders. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units awarded to the reporting person prior to the separation (the "Separation") of 2seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"). In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the Employee Matters Agreement by and between 2seventy and bluebird (the "EMA") to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on June 15, 2021 and vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders.
F2: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP").
F3: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP.
F4: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on April 29, 2013 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
F5: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 11, 2014 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
F6: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 4, 2015 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
F7: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 2, 2016 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
F8: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 8, 2017 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
F9: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 20, 2018 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
F10: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 6, 2019 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
F11: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 18, 2020 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
F12: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 15, 2021 and shall vest 100% on the earlier of June 15, 2022 or the date of the next annual meeting of the stockholders. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2019 Filed May 23, 2019 18:33 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 22,400 | $0.00 Strike: $25.04 | $0.00 |
DisclosureSEC source: 0001127602-19-019715 · form4.xml · derivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,400 Underlying: Ordinary Shares · 22,400 shares Expires 2029-05-22 F1 · derivative.exercise_date: This option becomes exercisable in full on 5/22/2020. Read SEC document |
| April 26, 2019 Filed Apr 29, 2019 21:07 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 12,472 | $0.00 Strike: $75.03 | $0.00 |
DisclosureSEC source: 0001209191-19-026436 · doc4.xml · derivative · entry 2 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,472 Underlying: Common Stock · 12,472 shares Expires 2029-04-25 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| April 26, 2019 Filed Apr 29, 2019 21:07 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 1,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-026436 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,907 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 20:44 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 188 | $86.01 | $16,169.88 |
DisclosureSEC source: 0001209191-19-022585 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,387 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:08 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 255 | $63.59 | $16,215.45 |
DisclosureSEC source: 0001209191-19-000889 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,199 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 20:15 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 235 | $69.08 | $16,233.80 |
DisclosureSEC source: 0001209191-18-053099 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,944 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:06 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 242 | $67.00 | $16,214.00 |
DisclosureSEC source: 0001209191-18-040933 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,709 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 16:19 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $183.10 | $0.00 |
DisclosureSEC source: 0001209191-18-039190 · doc4.xml · derivative · entry 2 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2028-06-20 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 20, 2019, or the date of the next annual meeting of stockholders. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 16:19 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-039190 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · security: These restricted stock units for common stock vest 100% on the earlier of June 20, 2019, or the date of the next annual meeting of stockholders Read SEC document |
| June 14, 2018 Filed Jun 19, 2018 00:47 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $21.64 | $0.00 |
DisclosureSEC source: 0001104659-18-040890 · a4.xml · derivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-14 F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 16:06 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantStock Option · Derivative | 105,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001485003-18-000089 · wf-form4_152900675083479.xml · derivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2028-06-11 F1 · derivative.exercise_date: The option was granted on June 12, 2018 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. Read SEC document |
| May 23, 2018 Filed May 24, 2018 18:22 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $45.64 | $0.00 |
DisclosureSEC source: 0001127602-18-018853 · form4.xml · derivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Ordinary Shares · 17,500 shares Expires 2028-05-23 F1 · derivative.exercise_date: This option becomes exercisable in full on 5/23/19. Read SEC document |
| May 01, 2018 Filed May 3, 2018 21:28 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $60.85 | $0.00 |
DisclosureSEC source: 0001209191-18-027750 · doc4.xml · derivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-04-30 F1 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in option plan). Read SEC document |
| March 29, 2018 Filed Apr 3, 2018 20:26 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 195 | $83.33 | $16,249.35 |
DisclosureSEC source: 0001209191-18-022963 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,467 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 21:12 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 171 | $94.71 | $16,195.41 |
DisclosureSEC source: 0001209191-18-000810 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,272 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 20:29 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 139 | $116.74 | $16,226.86 |
DisclosureSEC source: 0001209191-17-055126 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,101 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 20:23 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 129 | $125.91 | $16,242.39 |
DisclosureSEC source: 0001209191-17-043339 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,962 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 20:03 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.06 | $0.00 |
DisclosureSEC source: 0001104659-17-042941 · a4.xml · derivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-29 F1 · derivative.exercise_date: This stock option award was granted under Voyager Therapeutics, Inc.'s 2015 Stock Option and Incentive Plan pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy and will vest in full upon the first anniversary of the grant, subject to Ms. Dixon's continued service on the Board of Directors. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 16:56 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039201 · doc4.xml · derivative · entry 2 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2027-06-08 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 8, 2018, or the date of the next annual meeting of stockholders. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 16:56 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039201 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · security: These restricted stock units for common stock vest 100% on the earlier of June 8, 2018, or the date of the next annual meeting of stockholders Read SEC document |
| May 26, 2017 Filed May 31, 2017 20:30 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $134.38 | $0.00 |
DisclosureSEC source: 0001209191-17-036450 · doc4.xml · derivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-25 F1 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in option plan). Read SEC document |
| May 24, 2017 Filed May 25, 2017 18:02 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 14,200 | $0.00 Strike: $58.25 | $0.00 |
DisclosureSEC source: 0001127602-17-019448 · form4.xml · derivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,200 Underlying: Ordinary Shares · 14,200 shares Expires 2027-05-24 F1 · derivative.exercise_date: This option becomes exercisable in full on 5/24/18. Read SEC document |
| May 19, 2017 Filed May 23, 2017 16:41 UTC | Carisma Therapeutics Inc. EBIO · Entity 74418 | GrantStock Option · Derivative | 8,072 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001485003-17-000064 · wf-form4_149557209787052.xml · derivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,072 Underlying: Common Stock · 8,072 shares Expires 2027-05-18 F1 · derivative.exercise_date: The option was granted on May 19, 2017 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. Read SEC document |
| March 31, 2017 Filed Mar 31, 2017 21:21 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 121 | $133.67 | $16,174.07 |
DisclosureSEC source: 0001209191-17-023911 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,833 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 22:25 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001104659-17-000983 · a4.xml · derivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-01-03 F1 · derivative.exercise_date: These stock options were issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The shares of common stock underlying the options will vest in quarterly installments subject to continued service. Read SEC document |
| December 30, 2016 Filed Dec 30, 2016 22:13 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 162 | $100.27 | $16,243.74 |
DisclosureSEC source: 0001209191-16-157107 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,712 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 20:43 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 172 | $94.29 | $16,217.88 |
DisclosureSEC source: 0001209191-16-144329 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,550 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| May 22, 2006 Filed May 24, 2006 15:09 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,396 | $24.16 | $82,047.36 |
DisclosureSEC source: 0000014272-06-000146 · dix565.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · CMO & Pres, Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,003 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. Read SEC document |
| March 07, 2006 Filed Mar 9, 2006 22:09 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantExecutive Option (right to buy) · Derivative | 37,145 | $0.00 Strike: $22.73 | $0.00 |
DisclosureSEC source: 0000014272-06-000095 · dix529.xml · derivative · entry 5 DIXON WENDY L · CIK 0001202283 · CMO & Pres, Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,145 Underlying: Common Stock, $0.10 par value · 37,145 shares Expires 2016-03-06 F5 · derivative.exercise_date: Option is not exercisable until the closing share price of common stock achieves a price of at least 15% above the option grant price and remains at that price for seven consecutive trading days. Option vests 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant, but may not be exercised until the threshold is satisfied. Read SEC document |
| March 07, 2006 Filed Mar 9, 2006 22:09 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,508 | $22.73 | $34,276.84 |
DisclosureSEC source: 0000014272-06-000095 · dix529.xml · nonDerivative · entry 3 DIXON WENDY L · CIK 0001202283 · CMO & Pres, Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,399 F3 · shares: Shares withheld for payment of taxes. Read SEC document |
| March 07, 2006 Filed Mar 9, 2006 22:09 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 5,107 | $22.73 | $116,082.11 |
DisclosureSEC source: 0000014272-06-000095 · dix529.xml · nonDerivative · entry 2 DIXON WENDY L · CIK 0001202283 · CMO & Pres, Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,907 F2 · shares: Consists of shares earned as long-term performance awards under the 2002 Stock Incentive Plan. Read SEC document |
| March 07, 2006 Filed Mar 9, 2006 22:09 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 8,855 | $22.73 | $201,274.15 |
DisclosureSEC source: 0000014272-06-000095 · dix529.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · CMO & Pres, Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,800 F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| December 02, 2005 Filed Dec 6, 2005 20:31 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,977 | $21.69 | $42,881.13 |
DisclosureSEC source: 0000014272-05-000197 · dix468.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · CMO & Pres, Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,945 F1 · kind: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes shares of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| May 20, 2005 Filed May 23, 2005 17:03 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,936 | $25.64 | $100,919.04 |
DisclosureSEC source: 0000014272-05-000122 · dix400.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · CMO & Pres, Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,922 F1 · kind: Shares withheld for payment of taxes upon vesting of restricted stock. Read SEC document |
| March 01, 2005 Filed Mar 3, 2005 22:33 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantExecutive Option (right to buy) · Derivative | 46,667 | $0.00 Strike: $25.45 | $0.00 |
DisclosureSEC source: 0000014272-05-000067 · dix360.xml · derivative · entry 3 DIXON WENDY L · CIK 0001202283 · CMO & Pres, Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,667 Underlying: Common Stock, $0.10 par value · 46,667 shares Expires 2015-02-28 F3 · derivative.exercise_date: Option is not exercisable until the earlier of (i) the closing share price of common stock achieving a price of at least 15% above the option grant price and remaining at that price for seven consecutive trading days or (ii) the ninth anniversary of the grant date. Shares underlying option vest 25% a year, on a cumulative basis, commencing one year after the date of grant. Read SEC document |
| March 01, 2005 Filed Mar 3, 2005 22:33 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 7,778 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-05-000067 · dix360.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · CMO & Pres, Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,858 F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| December 03, 2004 Filed Dec 6, 2004 19:21 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,476 | $24.06 | $35,512.56 |
DisclosureSEC source: 0000014272-04-000195 · dix323.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · CMO & Pres, Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,080 F1 · kind: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes shares of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| March 02, 2004 Filed Mar 4, 2004 22:24 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantOption (right to buy) · Derivative | 45,333 | $0.00 Strike: $28.11 | $0.00 |
DisclosureSEC source: 0000014272-04-000069 · dix221.xml · derivative · entry 3 DIXON WENDY L · CIK 0001202283 · CMO & Pres, Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,333 Underlying: Common Stock, $0.10 par value · 45,333 shares Expires 2014-03-01 F3 · derivative.exercise_date: Exercisable as to 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant. Read SEC document |
| March 02, 2004 Filed Mar 4, 2004 22:24 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 7,556 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-04-000069 · dix221.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · CMO & Pres, Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,556 F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| September 10, 2003 Filed Sep 12, 2003 19:16 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-03-000027 · dix160.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · CMO & Pres, Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.